🔗 Share this article

Ministers and senior MPs have raised concerns that the United Kingdom's series of deals with the US administration are "lacking a solid foundation." This stems from revelations that a much-touted deal on medicines, which promises zero tariffs in exchange for the NHS increasing its costs, lacks any formal legal text beyond vague headline terms outlined by government press releases.

Lacking Legal Footing

The deal on drug tariffs, promoted as a "landmark" achievement, is still an "agreement in principle" without detailed provisions. It has been highlighted that the press releases from the UK and US governments present the deal in divergent terms. The British version celebrates securing "duty-free access" as a unique achievement, while the American announcement concentrates on the expectation for the NHS to pay significantly more for new medications.

"The danger exists that the UK government has promised concessions to raise drug prices in return for only a pledge from President Trump," commented David Henig, a trade expert. "It is documented he has a record of not following through on agreements."

Wider Concerns Amidst a Suspended Agreement

Worries have been amplified by Washington's move to pause the major technology agreement, which was previously described as "a huge leap forward" in the bilateral relationship. The US cited a insufficient movement from the UK on reducing other tariffs as the reason for the pause.

Additionally, concessions secured for British farmers as part of an earlier tariff deal have not been formally approved by the US, despite a imminent January deadline. "We have been informed that that the US has not yet signed off the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

Behind the scenes, ministers have admitted unease that the government's agreements with the US are unstable and unpredictable. One minister described the series of agreements as "built on sand," while another characterized the situation as the "new normal" in the transatlantic relationship, marked by "increased uncertainty and instability."

Layla Moran, a senior MP on the health committee, remarked: "What is even more astonishing than the US approach is the UK government's naive belief that his administration is a good faith actor. The NHS is of vital importance."

Official Reassurances and Concrete Outcomes

Officials have attempted to minimize the chances of the US reneging on the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been advocating for the agreement, seeking certainty on imports and pricing, making it less abstract than the paused tech deal.

Officials concede that unpredictability is inherent in dealing with the current US leadership. However, they contend that the UK has achieved real benefits for businesses, such as lower steel tariffs compared to other nations. "The fact we have 25% steel tariffs, which is lower than the rate for the rest of the world, is not flimsy," one official said.

However, delays have arisen in enacting the broader trade deal. Promised access for British beef have yet to be finalized, and the commitment to "remove tariffs on British steel and aluminium" has remains unmet, with tariffs remaining at 25%.

Moving forward, the two sides have planned to recommence talks on the suspended digital agreement in January, following what were described as "constructive" meetings between UK and US officials in Washington.